A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects With Common Warts (Verruca Vulgaris)
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2018
At a glance
- Drugs Cantharidin (Primary)
- Indications Warts
- Focus Therapeutic Use
- Acronyms COVE-1
- Sponsors Verrica Pharmaceuticals
- 13 Dec 2018 Planned number of patients changed from 20 to 55.
- 13 Dec 2018 Planned End Date changed from 8 Dec 2018 to 5 Jul 2019.
- 13 Dec 2018 Planned primary completion date changed from 6 Oct 2018 to 3 May 2019.